Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436


Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R.

Am J Cardiol. 2013 Mar 15;111(6):841-5. doi: 10.1016/j.amjcard.2012.11.058. Epub 2012 Dec 27.


A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.


Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin.

Laynez A, Sardi G, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2013 Feb 15;111(4):516-20. doi: 10.1016/j.amjcard.2012.10.035. Epub 2012 Dec 4.


Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).

Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK.

Am J Cardiol. 2014 Jan 1;113(1):64-9. doi: 10.1016/j.amjcard.2013.09.019. Epub 2013 Oct 3.


Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators.

N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.


Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Am Heart J. 2006 Oct;152(4):627-35.


Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E.

Am J Cardiol. 2011 Oct 1;108(7):905-11. doi: 10.1016/j.amjcard.2011.05.020. Epub 2011 Aug 2.


Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).

Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD.

JACC Cardiovasc Interv. 2014 Jun;7(6):604-12. doi: 10.1016/j.jcin.2014.01.160. Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946. Antman, Elliot M [Corrected to Antman, Elliott M].


Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.


Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators.

Circulation. 2007 Dec 18;116(25):2923-32. Epub 2007 Dec 3.


Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A.

J Am Coll Cardiol. 2013 May 21;61(20):2060-6. doi: 10.1016/j.jacc.2013.02.036. Epub 2013 Mar 21.


Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.


Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators.

Circulation. 2005 Jun 28;111(25):3366-73. Epub 2005 Jun 20.


Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.

Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL.

Int J Cardiol. 2013 Sep 20;168(1):523-8. doi: 10.1016/j.ijcard.2012.09.214. Epub 2012 Oct 16.

Items per page

Supplemental Content

Write to the Help Desk